Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study)

November 14, 2014 updated by: Tufts University
Several trials have found that nutritional supplementation can elicit an increased rate of skeletal muscle protein synthesis following a single bout of exercise in both young and older individuals. However, there have been no studies that have investigated if nutritional supplementation and exercise can cause a sustained increase in physical functioning and fat free mass, particularly in older adults with functional limitations. This study will compare the effects of a nutritional supplement versus a placebo on exercise training induced changes in physical functioning older adults who are at risk for mobility disability.

Study Overview

Detailed Description

Exercise Intervention: Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.

Supplement Intervention: Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.

Primary Outcome: The primary outcome will be the time to walk 400 meters, expressed as average gait speed during the 400 M walk. All participants must be able to walk 400 meters in <15 minutes at walking at their normal speed. The 400 M walk will be assessed at baseline, 3-months, and 6-months, with the changes at 6-months being the primary outcome.

Secondary Outcome Measures:

  • Stair Climb Test
  • Body Composition
  • Skeletal muscle cross sectional area
  • Isokinetic/Isometric peak torque/power
  • Hand-grip strength
  • Nutritional status
  • Quality of Life/Depressive symptoms Expected enrollment: 150 (80 at Tufts University (Boston, MA, USA), 70 at University of Uppsala (Uppsala, Sweden))

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Uppsala, Sweden, 75185
        • Uppsala University
    • Massachusetts
      • Boston, Massachusetts, United States, 02111
        • Jean Mayer Human Nutrition Research Center on Aging at Tufts University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years and older (OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male & Female ≥ 70 yrs
  2. Community dwelling
  3. Short Physical Performance Battery ≤ 9
  4. Willingness to be randomized and come to the laboratory for 6 months
  5. Body Mass Index < 35
  6. Mini-Mental State Examination >=24
  7. Serum 25 (OH) D (22.5 -50 nmol/l)
  8. Having obtained his/her informed consent
  9. Able to complete 400 M walk within 15 minutes

Exclusion Criteria:

  • • Acute or terminal illness; terminal illness with life expectancy less than 12 months, as determined by a physician

    • Current regular use (> 1 per week) of high protein oral nutritional supplements (eg: Boost, Exceed etc…)
    • Current use of Vitamin D supplements, >800 IU/day
    • Myocardial infarction in previous 6 months, symptomatic coronary artery disease, or congestive heart failure.
    • Upper or lower extremity fracture in previous 6 months.
    • Hemoglobin < 10 g/dL, Estimated GFR < 30 mL/min/1.73 m2
    • Uncontrolled hypertension (>150/90 mm Hg).
    • Neuromuscular diseases and drugs which affect neuromuscular function; severe progressive, degenerative neurologic disease
    • Hormone replacement therapy
    • Insulin-dependent diabetes mellitus
    • Milk protein allergy
    • Major surgery in the past 6 months (requiring general anesthesia)
    • Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention, e.g. renal failure on hemodialysis, severe psychiatric disorder (e.g. bipolar, schizophrenia)
    • Excessive alcohol use (>14 drinks per wk)
    • Participation in moderate intensity physical activity > 20 minutes/week
    • Inability to communicate due to severe, uncorrectable hearing loss or speech disorder
    • Severe visual impairment (if it precludes completion of assessments and/or intervention)
    • Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active inflammatory disease; wheelchair bound
    • Cancer requiring treatment in the past three years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer)
    • Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen
    • Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
    • Patient who cannot be expected to comply with treatment, as decided by the Principal Investigator and study physician.
    • Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the clinical site Principal Investigator and/or study physician.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Exercise
Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
EXPERIMENTAL: Supplement
Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
SHAM_COMPARATOR: Placebo
Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Walk 400 meters
Time Frame: 6-Month
The primary outcome will be the time to walk 400 meters, expressed as average gait speed during the 400 M walk. All participants must be able to walk 400 meters in <15 minutes at walking at their normal speed. The 400 M walk will be assessed at baseline, 3-months, and 6-months, with the changes at 6-months being the primary outcome.
6-Month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Roger Fielding, PhD, Tufts University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2011

Primary Completion (ACTUAL)

August 1, 2014

Study Completion (ACTUAL)

August 1, 2014

Study Registration Dates

First Submitted

February 27, 2012

First Submitted That Met QC Criteria

March 1, 2012

First Posted (ESTIMATE)

March 2, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

November 18, 2014

Last Update Submitted That Met QC Criteria

November 14, 2014

Last Verified

November 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on Supplement Intervention

Subscribe